Prostate Formula
Natural health product licensed in Canada
- Other names
- High Potency PROSTATE FORMULA Triple Protector
- Licence holder
- Total Health Anti-Aging Research Inc.
- NPN or DIN-HM
- 80081711
- Status
- Active licence
- Licence date
- 6 December 2017
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Zinc: up to 20 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 15 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Fruit Extract : Matériel brut sec Extraction ratio : 8.5:1 Dry plant equivalent : 1,275 milligramme Potency : 85 % Fatty acids | 150 milligramme | Not calculated |
| Cuivre Source : Gluconate de cuivre (II) | 1 milligramme | 2,000 µg |
| Sélénium Source : Sélénométhionine | 50 microgrammes | Not calculated |
| Zinc Source : Citrate de zinc | 10 milligramme | 20,000 µg |
| Linum usitatissimum Source : Graine(s) | 225 milligramme | Not calculated |
| Prunus africana Source : Écorce (tige) Potency : 12 % Phytosterols | 50 milligramme | Not calculated |
| Stérols végétaux libres Source : Glycine max - Graine Potency : 95 % Combined beta-Sitosterol, Campesterol and Stigmasterol | 75 milligramme | Not calculated |
| Vitamine E Source : d-alpha tocophérol | 83.75 mg AT | Not calculated |
| Vitamine E Source : d-alpha tocophérol | 125 UI | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Hypromellose, Citrate de calcium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | Not specified | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia. Source of antioxidants for the maintenance of good health. Source of essential fatty acids for the maintenance of good health. Source of omega-3 fatty acids for the maintenance of good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer.
- Effets indésirables connus
Hypersensitivity, such as an allergy, has been known to occur in rare cases; in which case, discontinue use.
Source
Official Health Canada record, licence 80081711
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.